The US Centers for Medicare & Medicaid Services is making it clear to Medicare Part D plans that GLP-1 drugs approved for cardiovascular indications can be covered under the prescription drug benefit – but it may not be clear until 2025 whether the agency actually expects them to do so.
The agency released a statement and formal guidance via email to Part D plans on March 21, answering a key...







